Radioligand Disposition and Metabolism — Key Information in Early Drug Development
Radioligand Disposition and Metabolism — Key Information in Early Drug Development
复制标题
放射性配体的处置和代谢——早期药物开发的关键信息
DOI：
10.1007/978-94-011-0429-6_5
复制
发表时间：
1995
影响因子：
4.7
通讯作者：
G. Sedvall
中科院分区：
文献类型：
--
作者：
C. Halldin;C. Swahn;L. Farde;G. Sedvall
大多数被认为对身体来说是异物的药物和其他有机化合物在体内会发生代谢变化。大多数药物通过低底物特异性要求的酶系统代谢，该系统主要存在于肝脏中，但药物代谢也可能发生在肾脏和肺中。通过代谢获得的各种产物根据浓度和动力学进行鉴定。药物代谢被描述为环境中潜在有害物质的解毒。这并不完全正确，因为所得产物和代谢物也可能有毒。药物可发生多种不同类型的生化反应，可分为四种主要类型，即氧化、还原、水解和合成。放射性药物与任何其他药物或化合物一样，在人体体内给药后容易发生化学转化。对于放射性药物，我们只关心母体化合物及其放射性代谢物[1]。
The majority of drugs and other organic compounds that are considered foreign to the body undergoes metabolic changes in vivo. Most drugs are metabolized by a system of enzymes of low substrate specificity requirement which is present mainly in the liver but drug metabolism may also take place in the kidneys and lungs. The various products obtained by the metabolism are identified in terms of concentrations and kinetics. Drug metabolism has been described as a detoxication of potentially harmful substances from the environment. This is not strictly true since the resulting products and metabolites can also be toxic. Drugs can undergo many different types of biochemical reactions, which can be divided into four main types, namely, oxidations, reductions, hydrolysis and synthesis. Radiopharmaceuticals are like any other drugs or compounds liable to chemical transformation after their administration in vivo to humans. For radiopharmaceuticals we are only concerned with the parent compound and its radioactive metabolites [1].
影响因子：
--
作者：
L. Farde;A. Nordström;F. Wiesel;S. Pauli;C. Halldin;G. Sedvall
通讯作者：
L. Farde;A. Nordström;F. Wiesel;S. Pauli;C. Halldin;G. Sedvall
碳 11 标记的 SCH 39166（一种新的选择性多巴胺 D-1 受体配体）的合成以及初步 PET 研究。
DOI：
10.1016/0883-2889(91)90105-a
发表时间：
1991
期刊：
International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes
影响因子：
--
作者：
Halldin,C;Farde,L;Barnett,A;Sedvall,G
通讯作者：
Sedvall,G
[11C]NNC 687 和 [11C]NNC 756，多巴胺 D-1 受体配体。
影响因子：
3.1
作者：
Halldin,C;Foged,C;Farde,L;Karlsson,P;Hansen,K;Grønvald,F;Swahn,CG;Hall,H;Sedvall,G
通讯作者：
Sedvall,G